vTv Therapeutics (VTVT) Operating Income (2016 - 2025)

Historic Operating Income for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$10.7 million.

  • vTv Therapeutics' Operating Income fell 6444.82% to -$10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.8 million, marking a year-over-year decrease of 2425.51%. This contributed to the annual value of -$24.2 million for FY2024, which is 518.39% up from last year.
  • Latest data reveals that vTv Therapeutics reported Operating Income of -$10.7 million as of Q3 2025, which was down 6444.82% from -$7.7 million recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Operating Income registered a high of -$1.6 million during Q3 2021, and its lowest value of -$11.1 million during Q4 2021.
  • Over the past 5 years, vTv Therapeutics' median Operating Income value was -$6.3 million (recorded in 2022), while the average stood at -$6.3 million.
  • Within the past 5 years, the most significant YoY rise in vTv Therapeutics' Operating Income was 4339.69% (2021), while the steepest drop was 70704.92% (2021).
  • Quarter analysis of 5 years shows vTv Therapeutics' Operating Income stood at -$11.1 million in 2021, then skyrocketed by 42.9% to -$6.3 million in 2022, then increased by 25.79% to -$4.7 million in 2023, then dropped by 3.93% to -$4.9 million in 2024, then crashed by 118.7% to -$10.7 million in 2025.
  • Its Operating Income was -$10.7 million in Q3 2025, compared to -$7.7 million in Q2 2025 and -$6.5 million in Q1 2025.